BAILLIE GIFFORD & CO 13D and 13G filings for Recursion Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2024-01-26 10:49 am Sale | 2023-12-29 | 13G | Recursion Pharmaceuticals, Inc. RXRX | BAILLIE GIFFORD & CO | 24,179,504 11.610% | -641,346 (-2.58%) | Filing |
2023-01-24 07:35 am Purchase | 2022-12-30 | 13G | Recursion Pharmaceuticals, Inc. RXRX | BAILLIE GIFFORD & CO | 24,820,850 13.660% | 2,697,695 (+12.19%) | Filing |
2022-01-27 10:18 am Purchase | 2021-12-31 | 13G | Recursion Pharmaceuticals, Inc. RXRX | BAILLIE GIFFORD & CO | 22,123,155 13.870% | 5,104,498 (+29.99%) | Filing |
2021-05-06 12:01 pm Purchase | 2021-04-30 | 13G | Recursion Pharmaceuticals, Inc. RXRX | BAILLIE GIFFORD & CO | 17,018,657 10.890% | 17,018,657 (New Position) | Filing |